Gene expression of p21, <i>TP53</i>, and MDM2 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated in Table 1.

<p>(A) <i>TP53</i>. (B) p21. (C) MDM2.</p

List of genes significantly up-regulated in Nutlin-3a resistant cancer cell lines with wild-type <i>TP53</i>.

<p>List of genes significantly up-regulated in Nutlin-3a resistant cancer cell lines with wild-type <i>TP53</i>.</p

Protein expression of <i>TP53</i> and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated in Table 1.

<p>C, untreated control; *, cancer cell lines carrying <i>TP53</i> mutation. Het, heterozygous TP53 mutation; hom, homozygous <i>TP53</i> mutation.</p

Cell viability of ovarian cancer cell lines treated with Nutlin-3a.

<p>All 15 cell lines were plated at a density of 1 × 10³ cells per well in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.</p

<i>TP53</i> mutation status and Nutlin-3a sensitivity of ovarian cancer cell lines.

<p>ATCC, American Type Culture Collection; JCRB, Japanese Collection of Research Bioresources Cell Bank.</p><p><i>TP53</i> mutation status and Nutlin-3a sensitivity of ovarian cancer cell lines.</p

Patient characterisitics.

<p>Patient characterisitics.</p

Unsupervised hierarchical clustering of CNAs identifies distinct patient subgroups.

<p><b>A</b>) Unsupervised hierarchical clustering of raw log2 ratios derived from 72 serous type ovarian cancers. Copy number values are color coded as follows: blue (loss), white (normal) and magenta (gain). The pattern of dendrogram suggests two major genomic subgroups within the grade 3 tumors. <b>B</b>) PFS Kaplan-Meier plot for the two subgroups. <b>C</b>) Comparison of clinical characteristics between the patient subgroups. Histology: red = serous; Grade: orange = grade 2, yellow = grade 3; Stage: red = Ic, blue = II, green = IIc, yellow = IIIa, orange = IIIb, brown = IIIc, pink = IV, dark gray = IVa; Status: red = evidence of disease, blue = no evidence of disease; Outcome: green = complete remission, orange = progression, yellow = partial remission, brown = lost to follow up, pink = benign; 6 month progression: red = yes, blue = no, green = P (progression); Recurrence: brown = yes, orange = persistent disease, yellow = no; Platinum response: red = sensitive, black = resistant; Drug: blue = yes, light blue = no; Ascites: red = yes, black = no; Chemo: orange = yes, brown = no; Radiation: red = yes, black = no; General: white = n/a and/or blank.</p

A–E.

<p>Representative aCGH profiles of 5 ovarian carcinomas. Log2 ratios (y axis) are plotted along the chromosomes (x axis). Each tumor showing many CNAs including gain and loss of entire chromosome and/or chromosome arms, interstitial deletions, and high-level amplifications (indicated in red arrows). Some tumors had more than 10 high-level amplifications. <b>F.</b> Genomic profiles of 72 primary ovarian carcinomas generated by oligonucleotide array CGH. Each column in the left panel represents a tumor sample and rows represent losses and gains of DNA sequences along the length of chromosomes 1 through X as determined by the segmentation analysis of normalized log2 ratios. The color scale ranges from blue (loss) through white (two copies) to red (gain). The right panel indicates the frequencies of gain and loss of oligonucleotide probes on a probe-by-probe basis for all autosomes and the X chromosome. The color scale ranges from white (no changes) to blue (frequent changes). Amplification of 3q26.2 and 8q24.12 including the <i>EVI1</i> and <i>MYC</i> oncogenes and deletion of 16q24.2 and 22q13.33 were the most frequent alterations observed in 75% and 78% of the ovarian carcinomas respectively. <b>G.</b> Overall frequency of CNAs in 72 high-grade serous ovarian carcinomas. <b>H and I.</b> GISTIC analysis of copy number gains (<b>H</b>) and losses (<b>I</b>) in ovarian carcinomas. The statistical significance of the aberrations identified by GISTIC are displayed as false discovery rate q values to account for multiple hypothesis testing (q values; green line is 0.25 cut-off for significance). Scores for each alteration are plotted along the x-axis and the genomic positions are plotted along the y-axis; dotted lines indicate the centromeres. <b>H</b>) GISTIC revealed twenty broad and focal regions of gain (copy number threshold = log2 ratio ≥0.4). <b>I</b>) Loss of both broad and focal regions were identified by GISTIC (copy number threshold = log2 ratio≤0.4 for broad and ≤0.1 for focal events). Twenty broad and focal regions of losses, including seven focal events, were identified in the background of broad regions. Candidate genes for some broad and focal events are noted. Green stars indicate known or presumed copy number polymorphisms.</p

GISTIC analysis of patient subgroups.

<p><b>A–B</b>) Cluster 1; <b>C–D</b>) Cluster 2 amplification and deletion peaks defined by GISTIC in two patient subgroups show clear difference in the location of peaks. Green stars indicate major differences between the two subgroups. Probes from these regions were used to build the model for training.</p

Validation of classification accuracy in UCSF-GOG dataset.

<p>Kaplan-Meier plot for UCSF-GOG subgroups identified through supervised clustering. Subgroups are clinically distinct with regard to overall survival (p = 0.028).</p